Introduction
============

Adenosine receptors (ARs) are G protein-coupled receptors (GPCRs) that sense an imbalance of demand and supply of energy/oxygen/nutrients. Extracellular adenosine concentrations rise in response to hypoxia and other stress, to act upon four subtypes of ARs (A~1~AR, A~2A~AR, A~2B~AR, and A~3~AR) ([@B60]; [@B24]). As shown with mice lacking all four AR subtypes, extracellular adenosine is mainly a sensor of tissue damage or danger, rather than a homeostatic regulator under baseline conditions ([@B163]). Elevated adenosine can correct an energy imbalance during distress of an organ, for example by slowing the heart rate by A~1~AR activation or increasing the blood supply to heart muscle by the A~2A~AR ([@B16]). However, there are conditions in which chronic adenosine overproduction can be harmful, leading to increased inflammation, fibrosis, cytokine release, brain dopamine depletion, and kidney damage ([@B17]). Moreover, exogenous AR agonists, antagonists, or allosteric modulators can be applied for therapeutic benefit, and thousands of such agents have been reported by medicinal chemists working toward that goal ([@B85]; [@B95]). Clinically important effects of adenosine also include suppression of the immune response, glomerular filtration, seizures and pain ([@B60]; [@B23]; [@B7]). Adenosine 5′-triphosphate (ATP) released from cells under stress conditions or damage is the source of much of the extracellular adenosine. There is typically a basal level of AR stimulation, especially for A~1~AR, A~2A~AR and A~3~AR at low nM concentrations, while A~2B~AR activation generally occurs at higher (μM) adenosine concentrations ([@B60]). Therefore, AR antagonists have distinct biological effects *in vivo*. Purinergic signaling is also to be considered in the larger context of ligand (ATP)-gated P2X receptors or G protein-coupled P2Y receptors that respond to extracellular purine and pyrimidine mono- and di-nucleotides ([@B19]).

There are many approaches to small molecule therapeutics based on experimental modulators of ARs ([@B24]; [@B18]). Numerous subtype-selective agonists and antagonists have been introduced, both as pharmacological probes and as clinical candidate molecules, and representative compounds are described here. AR knockout (KO) mice are increasingly used to validate *in vivo* results with agonists and antagonists, which can actually have variable selectivity ([@B20]). This review covers both directly acting AR modulators, i.e., agonists, and several positive allosteric modulators (PAMs). It describes compounds that have been in human trials, for both therapeutics and diagnostics, and some compounds for which clinical trials have only been contemplated. Other reviews cover the use of enzymatic or transport inhibitors to increase -- such as inhibitors of adenosine kinase or adenosine deaminase that deplete adenosine levels, or uptake inhibitors -- or to decrease, such as inhibitors of ectonucleotidases, the levels of endogenous nucleosides ([@B15]; [@B3]; [@B158]). These enzymes are often upregulated in inflammatory states ([@B15]; [@B77]).

AR Agonists for Clinical Development
====================================

Agonists of the A~1~AR, A~2A~AR and A~3~AR have been the subject of preclinical and clinical evaluation ([Figure 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). A~2B~AR agonist development is the most limited among the ARs, and agonists for this AR subtype have not yet entered clinical trials. There is also much controversy about whether A~2B~AR agonists or antagonists would be more useful clinically ([@B47]; [@B139]; [@B66]).

![Adenosine **(1)**, a non-selective AR agonist, and its derivatives as A~1~AR-selective agonists, including nucleosides **(2**--**16)** and non-nucleosides **(17**--**20)**.](fncel-13-00124-g001){#F1}

![A~2A~AR- **(21**--**29)** and A~2B~AR- **(30)** selective agonists.](fncel-13-00124-g002){#F2}

###### 

Representative recent clinical trials of AR agonists and an A~1~AR PAM (data from [ClinicalTrials.gov](http://ClinicalTrials.gov), accessed 12-28-2018).

  Receptor      Condition                  Compound   Years        Phase, NCT\#        Reference
  ------------- -------------------------- ---------- ------------ ------------------- ----------------
  A~1~          Neuropathic pain           **1**      2014--2018   **2**, 00349921     [@B168]
                SVT^a^                     **1**      2011--2017   **-**, 01495481     [@B29]
                Perioperative pain         **1**      2006         **2**, 00298636     [@B91]
                Pediatric heart transpl.   **1**      2015--2018   **1**, 02462941     [@B58]
                Takotsubo syndrome         **1**      2016--2018   **2**, 02867878     [@B61]
                Paroxysmal AF              **1**      2017         **2**, 03032965     [@B106]
                Glaucoma                   **4**      2015--2016   **3**, 02565173     [@B117]
                Neuropathic pain           **9**      2002--2003   **2**, 00376454     [@B50]
                T2D                        **10**     ∼2009        **1**, **-**        [@B137]
                AF                         **13**     2008--2014   **2**, 00713401     [@B35]
                AF                         **14**     2015--2018   **2**, 00040001     [@B50]
                Stable angina              **17**     2007--2011   **2**, 00518921     [@B142]
                AF                         **17**     2008         **2**, 00568945     [@B95]
                Heart failure^b^           **19**     2014--2016   **2**, 02040233     [@B103]
                Heart failure^c^           **19**     2016--2018   **2**, 02580851     [@B157]
                Posthepetic neuralgia      **39**     2008--2012   **2**, 00809679     [@B113]
  A~2A~         CAD (MPI)                  **21**     2005--2009   **3**, 00208312     [@B167]
                Sickle cell anemia         **21**     2013--2018   **2**, 01788631     [@B55], [@B54]
                Lung transplant            **21**     2017-        **1**, 03072589     [@B135]
                IHD (MRI)                  **21**     2011--2012   **1**, 00881218     [@B104]
                Pulmonary hypertens.       **21**     2014--2018   **-**, 02220634     [@B122]
                Heart transplant (MRI)     **21**     2017-        **4**, 03102125     [@B122]
                BBB defect                 **21**     2015--2018   **1**, 02389738     [@B83]
                Diabetic nerve pain        **22**     2007--2014   **2**, 00452777     [@B97]
                Diabetic foot ulcers       **23**     2006--2012   **2**, 00318214     [@B114]
                CAD                        **24**     2009--2012   **3**, 00944294     [@B167]
                CAD (SPECT-MPI)            **25**     2009--2012   **3**, 00990327     [@B167]
                CAD (MPI)                  **25**     2011--2012   **3**, 01313572     [@B167]
                COPD                       **28**     2007--2013   **2**, 00430300     [@B110]
                Healthy subjects (PK)      **29**     2012--2017   **1**, 01640990     [@B4]
  A~2B~- A~3~                              --         --                               [@B139]
                Rheumatoid arthritis       **31**     2016-        **3**, 02467762     [@B56]
                Plaque psoriasis           **31**     2017-        **3**, 03168256     [@B39];
                Glaucoma                   **31**     2009--2015   **2**, 01033422     [@B84]
                Dry eye disease            **31**     2010--2015   **3**, 01235234     [@B9]
                NASH                       **32**     2016-        **2**, 02927314     [@B57]
                HCC                        **32**     2008--2015   **1/2**, 00790218   [@B138]
                HCC                        **32**     2014-        **2**, 02128958     [@B138]
                Chronic HCV                **32**     2008--2015   **1/2**, 00790673   [@B12]

a

Comparison to dexmedetomidine.

b

With preserved ejection fraction.

c

With reduced ejection fraction. SVT, supraventricular tachycardia; AF, atrial fibrillation; CAD, coronary artery disease; MPI, myocardial perfusion imaging; MRI, magnetic resonance imaging; SPECT, single-photon emission computed tomography; BBB, blood brain barrier; IHD, ischemic heart disease; PK, pharmacokinetics; NASH, nonalcoholic steatohepatitis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.

###### 

AR Binding affinity of selected AR agonists described here (human, if not specified; p, pig; r, rat; m, mouse).^a,b^

  Compound                  pK~i~ A~1~AR         pK~i~ A~2A~AR        pK~i~ A~3~AR
  ---------- -------------- -------------------- -------------------- ----------------
  1          Adenosine      7.0                  6.5                  6.5
  2          Metrifudil     7.22 (r)             7.62 (r)             7.33, 7.46 (r)
  3          CPA            8.64, 9.66 (m)       6.10, 6.09 (m)       7.37, 6.27 (m)
  4          Trabodenoson   9.0                  ND                   ND
  5          CHA            8.62                 5.86                 7.14
  6          SDZ WAG994     7.64 (p), 7.12 (r)   4.64 (p), 5.24 (r)   ND
  7          Cl-ENBA        9.29, 9.70 (m)       5.87                 5.89, 5.62 (m)
  8          MRS7469        8.67, 9.43 (m)       5.45                 4.97, 6.05 (m)
  10         GS 9667        7.92                 \<5                  \<6
  11         GR79236X       8.51 (r)             5.89 (r)             ND
  13         Tecadenoson    8.52                 ND                   ND
  14         Selodenoson    8.22                 ND                   ND
  15         NNC 21-0136    8.33 (r)             5.89 (r)             ND
  16         MRS5474        7.30                 5.40                 6.33
  17         Capadenoson    8.85                 \<5                  \<5
  18^c^      Neladenoson    10.0                 6.17                 \<5.52
  20         MMPD           9.31, 9.68 (r)       7.15, 7.28 (r)       \<5
  21         Regadenoson    \<5, 8.11 (m)        6.34, 7.11 (m)       \<5, \<5 (m)
  22         BVT.115959     6.81                 6.01                 6.81
  23         Sonedenson     \<5                  6.31                 ND
  24         Binodenoson    4.32                 6.57                 \<4
  25         Apadenson      7.11                 9.30                 7.35
  26         Evodenoson     7.24                 9.15                 6.60
  27^c^      UK-371104      6.99                 7.70                 \<6
  28         UK-432097      ND                   8.40                 ND
  29         GW328276X      6.05                 8.63                 8.38
  30         Bay 60-6583    6.41, 6.45 (m)       \<5, \<5 (m)         6.94, 6.87 (m)
  31         Piclodenoson   7.29, 7.79 (m)       5.50, 5.54 (m)       8.74, 9.66 (m)
  32         Namodenoson    6.66                 5.27                 8.85
  33         LJ-529         6.71                 6.65                 9.42
  34         CP-532,903     6.05 (m)             \<5 (m)              8.05 (m)
  35         CP-608,039     5.14                 \<4.3                8.24
  36         MRS5698        \<5                  \<5                  8.52
  37         MRS5980        \<5                  \<5                  9.15
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Each AR can signal through multiple pathways, and different agonists may show a signaling preference, i.e., bias. For example, the A~2B~AR acts through G~s~, G~q~, or G~i~, depending on the tissue, receptor density and final measure of activity ([@B65]). The possibility of biased signaling of AR agonists or PAMs could provide a means to increase selectivity for a particular tissue or condition ([@B67]; [@B10]; [@B65]; [@B152]).

One limitation of AR agonists for human therapeutics is that their target GPCRs might be subject to agonist-induced desensitization as shown for all four ARs in cell lines ([@B115]). However, in other cases, depending on multiple pharmacological factors, a prolonged agonist exposure did not lead to *in vivo* desensitization of the desired effect ([@B108]), even with a full A~3~AR agonist. Two possible approaches to circumvent GPCR desensitization are the use of partial agonists in cases where the desired effect is maintained, such as in A~1~AR antiarrhythmic activity ([@B50]; [@B157]), and the use of PAMs ([@B155]). Partial agonists are also known to display tissue or organ selectivity, because of the differential receptor expression level ([@B150]). Thus, when spare receptors are present, i.e., overexpression or high level of endogenous expression, a partial agonist could be fully efficacious in tissues where there is a receptor reserve and activation of only a fraction of the receptors suffices.

Positron emission tomography (PET) for *in vivo* imaging of ARs has been extensively explored ([@B151]). PET imaging could potentially be essential in drug discovery and clinical development of AR modulators, to determine the target engagement and to assess the role of endogenous adenosine. Although most high affinity ligands designed for *in vivo* AR imaging by PET have been antagonists, some agonists have also been labeled with positron-emitting ^18^F, ^76^Br or ^11^C isotopes ([@B94]; [@B75]).

A~1~AR and A~2A~AR are examples of the growing list of GPCRs for which physically determined three-dimensional structures with a bound agonist are known ([@B105]; [@B164]). This understanding facilitates the structure-based design of novel AR agonists ([@B147]). Several structures determined by X-ray crystallography and cryo-electron microscopy contain a G-protein or G-protein fragment, which is more representative of the active state AR structures ([@B42]; [@B69]). NMR studies of assigned A~2A~AR Trp and Gly residues are informative about microswitches involved in the signal propagation from bound agonist toward the intracellular region for G protein binding ([@B44]). There can be multiple active conformations of a given GPCR, and agonist-induced changes are nuanced with respect to both structure and signaling. Thus, direct biophysical methods for receptor characterization can impact agonist design.

The following examples of AR drugs and molecular probes are arranged according to their target receptor: A~1~ (**1** -- **20**, **39**, **40**), A~2A~ (**21** -- **29**), A~2B~ (**30**), A~3~ (**31** -- **38**, **41**). It has also been suggested that coactivation of two AR subtypes might be beneficial, such as both A~1~AR and A~3~AR in cardioprotection ([@B87]).

Early AR Agonists
-----------------

### Adenosine **1**

#### Arrhythmias

Many pathophysiological conditions including hypoxia and ischemia may cause arrhythmias. Adenosine is considered as an endogenous antiarrhythmic agent partly due to its endogenous anti-ischemic property ([@B95]; [@B140]). As described earlier, infused adenosine (under the name of Adenocard, approved in 1989, [@B121]) and its precursor ATP have long been used for the treatment of paroxysmal supraventricular tachycardia (PSVT) ([@B124]; [@B140]). The antiarrhythmic action of adenosine has been suggested to occur via the A~1~AR in the sinoatrial and atrioventricular nodes, which leads to modification of AV nodal conduction ([@B95]). A~1~AR activation is known to induce opening of ATP-sensitive potassium channels ([@B60]; [@B85]). Adenosine infusion (under the name of Adenoscan, approved in 1995) is used for myocardial perfusion imaging (MPI), through its short-lived A~2A~AR activation, to dilate the coronary artery ([@B121]). Many recent clinical trials in various cardiovascular and ischemic conditions have utilized adenosine as an approved drug being tested for new uses ([Table 1](#T1){ref-type="table"}). For example, a clinical trial of adenosine to reverse left ventricular impairment in Takotsubo syndrome ([@B61]) was initiated, but terminated in 2018.

#### Dermatological conditions

Adenosine applied topically has been used to promote hair growth and skin health ([@B1]; [@B51]). For the treatment of androgenetic alopecia, adenosine (0.75% solution) displayed efficacy similar to minoxidil but was preferred by patients because of the response speed and its quality. Applied in cosmetic preparations (0.1% cream or 1% dissolvable film) for 2 months, adenosine significantly improved skin smoothness and reduced facial wrinkles.

#### Epilepsy

Adenosine is considered an endogenous antiseizure agent and also attenuates epileptogenesis by an epigenetic mechanism, i.e., nuclear adenosine reduces DNA methylation ([@B15]). Elevated adenosine indirectly inhibits DNA methyltransferases through two stages of enzymatic product inhibition, beginning with *S*-adenosylhomocysteine hydrolase (SAH). In the epileptic brain there is an overexpression of adenosine kinase in astrocytes, which depletes adenosine both inside and outside the cell. Because peripheral adenosine itself is rapidly removed from circulation in seconds, drug delivery systems are needed to raise its brain concentration. Experimental use of an adenosine-releasing silk brain implant was found to be an efficacious form of adenosine augmentation therapy (AAT) for treating refractory epilepsy in a rat model of kindling epileptogenesis ([@B141]). Adenosine was encapsulated in microspheres, which were embedded into nanofilm-coated silk fibroin scaffolds. The polymer was introduced surgically into the infrahippocampal cleft, and when monitored for 10 days, demonstrated a lack of convulsive seizures. This protective effect was antagonized by an A~1~AR-selective antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX).

### AMP (Adenosine 5′-Monophosphate) and ATP (Adenosine 5′-Triphosphate)

#### Asthmatic drug testing

Ectonucleotidases readily cleave the naturally occurring 5′-phosphoesters of adenosine 5′-phosphates to produce adenosine *in situ*. Adenosine 5′-monophosphate (AMP) is used diagnostically in inhalation challenge testing ([@B13]; [@B82]). AMP readily forms adenosine *in situ* and thus most of its actions occur through ARs, but not all of its *in vivo* effects arise from AR activation ([@B20]; [@B163]).

#### Cancer

Adenosine 5′-triphosphate plays a physiological role in obstructive airway disease to increase inflammation and to induce bronchoconstriction and cough ([@B125]). ATP has been administered in humans intravenously in clinical trials for the treatment of both cachexia in cancer and the cancer itself ([@B126]). The working hypothesis was that by increasing the intracellular ATP pools in erythrocytes, the energy balance could be restored. Alternatively, an action on P2 receptors was considered, but the extracellular ATP pools were elevated only briefly in patients with advanced solid tumors. Nevertheless, with the ubiquitous presence of ectonucleotidases, one main action of ATP would be through increased adenosine acting at ARs.

### Metrifudil **2**

#### Glomerulonephritis

Many adenosine derivatives found in early studies (1960s and 1970s) to be biologically active at what were later termed the A~1~AR and A~2A~AR, contain bulky, hydrophobic substitution at the adenine *N*^6^ position ([@B121]; [@B85]; [@B110]). This describes two potent agonists, Metrifudil **2** and *R*-PIA (*R*-*N*^6^-phenylisopropyladenosine (structure not shown), which are moderately A~1~AR-selective. Metrifudil (60 mg oral dose) was one of the earliest synthetic adenosine agonists to be studied in humans ([@B131]; [@B161]), along with *R*-PIA ([@B132]). Following the discovery that vasodilator dipyridamole (equilibrative adenosine transporter ENT1 inhibitor) was active against glomerulonephritis by an adenosinergic mechanism, Metrifudil was applied to its treatment, which resulted in limited improvement in three patients. However, no subsequent trials of Metrifudil or *R*-PIA were reported, probably because of their cardiovascular side effects.

A~1~AR-Selective Agonists
-------------------------

### Trabodenoson (INO-8875, PJ-875) **4**

#### Glaucoma

A~1~AR partial agonist Trabodenoson (INO-8875) **4**, which is a 5′-nitrate ester derived from CPA **3**, was in advanced clinical trials as an ophthalmic formulation for primary open-angle glaucoma and ocular hypertension. However, the development was terminated in 2017 following a Phase 3 trial due to failure to achieve its primary endpoint ([@B84]). Trabodenoson and its congeners were also considered for treatment of arrhythmias ([@B50]; see below). Another analog containing a 5′-nitrate ester, but with a *N*^6^-3-aminotetrahydrofuryl group was found to lose its nitro group *in vivo* to form the parent full agonist, which was associated with side effects.

### CHA **5**

#### Hypothermia

The use of A~1~AR agonist CHA **5** for inducing therapeutic hypothermia has been proposed ([@B92]). However, it is likely that the hypothermic effect of CHA in rodents may be through both a peripheral A~3~AR, and a central A~1~AR ([@B21]).

### SDZ WAG994 **6**

#### Diabetes and obesity

A~1~AR is highly expressed in adipose tissue and involved in triglyceride (TG) storage. Breakdown of TG and the subsequent increase in plasma free fatty acids (FFA) results in development of insulin resistance in peripheral organs. Insulin resistance is associated with obesity and development of type 2 diabetes ([@B6]). Adenosine-mediated A~1~AR activation or A~1~AR overexpression in adipocytes results in suppression of lipolysis and reduction of plasma FFA. Various adenosine analogs have been developed for their potential intervention in diabetes. *N*^6^-Cyclopentyladenosine (CPA, **3**) reduced FFA and cholesterol levels and increased glycogen synthesis in skeletal muscle in streptozotocin (STZ) diabetic rats ([@B27]). Thus, A~1~AR agonists may have beneficial effects on glucose utilization by peripheral tissues to lower plasma glucose.

Typically, both 2′- and 3′-hydroxyl groups are important for nucleoside recognition in the AR binding sites. SDZ WAG994 **6** is a structurally unusual 2′-*O*-methyl A~1~AR agonist that did not display hemodynamic side effects in humans. However, SDZ WAG994 increased PR interval, consistent with A~1~AR activation in the AV node and its suggested use in tachycardia ([@B88]).

SDZ WAG994 **6** was also under development as an antilipolytic agent for treating diabetes ([@B81]). Oral administration of SDZ WAG994 and another A~1~AR agonist Selodenoson (RG14202, **14**) in STX-treated rats decreased FFA, TG levels and heart rate in a dose-dependent manner ([@B36]). A human study revealed that RPR749 (structure not shown), was capable of decreasing circulating FFA levels and thus may be beneficial in treating hyperlipidemia ([@B134]). These compounds have therapeutic potential for the treatment of cardiovascular and metabolic disorders.

### Cl-ENBA **7** and MRS7469 **8**

#### Hypothermia and pain

Several A~1~AR agonists, Cl-ENBA **7** and MRS7469 **8**, were recently reported to activate in the mouse A~1~AR in the brain when administered peripherally, without comparable peripheral A~3~AR activation ([@B21]; [@B147]). Cl-ENBA **7** is a highly A~1~AR-selective adenosine agonist that is used as a pharmacological probe ([@B147]), and its efficacy in pain models demonstrated ([@B109]). It consists of a mixture of two diastereoisomers, and thus its *in vivo* A~1~AR target engagement is complicated. However, when administered intraperitoneally in mice, it activated the central A~1~AR preferentially over the peripheral A~3~AR in mast cells, due partly its being a full agonist for the A~1~AR but a partial agonist of low efficacy or an antagonist at the A~3~AR ([@B21]). This is consistent with a report that *S*-*N*^6^-endo-norbornyl-adenosine (*S*-ENBA) is a full agonist at the A~1~AR but low-efficacy partial agonist at the A~3~AR ([@B64]).

Like Cl-ENBA, MRS7469 **8** is a highly selective agonist that activated the central A~1~AR preferentially when administered peripherally, leading to A~1~AR-dependent hypothermia and locomotor depression ([@B147]). When administered icv. (52 μg/kg) it caused intense hypothermia. Thus, it crosses the blood brain barrier (BBB) sufficiently, given its high affinity (K~i~ 0.37 nM at mouse A~1~AR), to activate the A~1~AR. Moreover, MRS7469 with a non-chiral *N*^6^ group is a pure diastereoisomer, which is advantageous for *in vivo* studies.

### GW493838 **9**

#### Pain

The A~1~AR is involved in depressant and protective functions in the brain and spinal cord, including suppressing pain ([@B129]; [@B168]; [@B70]). Intrathecal opioids induce local adenosine release ([@B45]), and exogenously applied adenosine and other A~1~AR agonists and PAMs reduce pain ([@B46]; [@B155]). A~1~AR agonist GW493838 **9**, which is an adenosine analog highly modified at *N*^6^ and 5′ positions, showed efficacy in animal models of pain ([@B79]). However, GW493838 (50 mg oral dose) failed to show significant efficacy in a clinical trial for treatment of chronic pain (diabetic pain). Also, a meta-analysis of patient postoperative pain in clinical data showed no analgesic effect of adenosine ([@B91]).

### CVT-3619 (GS-9667) **10,** GR79236 **11** and ARA **12**

#### Diabetes

Increasing evidence indicates a crucial role of A~1~AR in the regulation of insulin sensitivity and glucose homeostasis especially in metabolically active organs such as adipose tissue, liver and skeletal muscle, which are related to diabetes mellitus ([@B123]). It has been convincingly demonstrated that A~1~AR is critical for regulation of lipid metabolism, and thus A~1~AR agonists have been proposed for the treatment of type II diabetes (T2D) and obesity ([@B7]). The white adipocyte A~1~AR inhibits lipolysis. Curiously, a functional A~2A~AR activates thermogenic brown adipose tissue (BAT) as indicated using human PET imaging ([@B102]), and A~2A~AR agonists might prove beneficial in metabolic conditions ([@B148]). Cold exposure in human subjects reduced PET ligand binding in BAT, indicative of elevated local adenosine release.

Several A~1~AR agonists, GR79236 **11**, ARA **12**, and CVT-3619 **10**, have been in clinical trials for T2D due to their ability to increase insulin sensitivity ([@B14]; [@B95]; [@B137]). However, development of full agonists, such as GR79236 and ARA, was not successful due to cardiovascular side effects ([@B50]). Although both full and partial agonists may lower non-esterified fatty acid levels, it is suggested that partial agonists may improve insulin sensitivity without producing severe cardiovascular side effects ([@B50]). A single dose of ARA given to healthy individuals during a phase I clinical trial reduced plasma FFA levels, but individuals developed tolerance to the drug ([@B165]). The A~1~AR partial agonist CVT-3619 (GS-9667) has been reported to lower FFA in both healthy and obese subjects without showing evidence of A~1~AR desensitization ([@B137]), but oral doses of ≥ 300 mg were required to see the FFA effect. The individual benefits of GS-9667 and sitagliptin \[Januvia, an inhibitor of DPP4 (dipeptidyl peptidase 4)\] on glucose and lipid homeostasis were enhanced in combination ([@B120]).

### Tecadenoson **13** and Selodenoson **14**

#### Arrhythmias

Despite its demonstrated A~1~AR-dependent beneficial effect in PSVT, adenosine is known to cause atrial fibrillation (AF) in about 15% of patients by decreasing the refractory period of the atrium and causes other adverse effects related to the activation of other AR subtypes ([@B71]). Thus, extensive efforts have been made in developing selective A~1~AR agonists as anti-arrhythmic agents ([@B111]). A~1~AR full agonists Tecadenoson **13** ([@B35]), Selodenoson **14** and Trabodenoson **4** ([@B95]; [@B111]) have been under development. However, full agonists are known to cause tachyphylaxis, presumably due to A~1~AR desensitization. Tecadenoson has been in a Phase 3 trial for the termination of supraventricular tachycardia (SVT) ([@B50]; [@B111]), but its development was discontinued in 2009. A clinical safety study of Tecadenoson for the treatment of AF was performed, but its clinical development was also curtailed.

### NNC-21-0136 **15**

#### Stroke

NNC-21-0136 **15** is an A~1~AR selective agonist that was designed for neuroprotection. Its hemodynamic effects were minimal, revealing a brain-protective effect in stroke models ([@B98]; [@B88]), but it did not enter human testing.

### MRS5474 **16**

#### Seizures and depression

A~1~AR agonists are of interest in the CNS for their anxiolytic, antinociceptive, antidepressant and antiseizure properties, and behavioral results with A~1~AR KO mice support the use of A~1~AR in this context. Unfortunately, many adenosine derivatives display minimal ability to cross the BBB ([@B130]; [@B147]). 4′-Truncated nucleosides, thionucleosides and methanocarba-nucleosides (containing a \[3.1.0\]bicyclohexyl ring system) were originally characterized as A~3~AR low-efficacy, selective partial agonists. However, an *N*^6^-dicyclopropylmethyl group present in MRS5474 **16** substantially shifts the selectivity toward A~1~AR, especially in mouse (204-fold compared to mouse A~3~AR), compared to other a-branched *N*^6^ groups ([@B146], [@B147]; [@B21]). The small molecular weight (376), polar surface area (93 Å^2^) and number of H-bond donor groups (3) positioned MRS5474 for potential brain application. MRS5474 showed antidepressant activity in a mouse model that was mediated by homer1 protein in the medial prefrontal cortex, and upregulation of homer1 by an AR agonist was lost in A~1~AR KO mice ([@B133]). Nevertheless, it also activated a peripheral mA~3~AR ([@B21]).

### Capadenoson **17** and Neladenoson **18**

#### Angina

Anti-ischemic effect of A~1~AR agonists has been demonstrated in animal studies, but clinical successes are lacking, and more relevant clinical models are needed ([@B16]; [@B104]).

Most known AR agonists are adenosine derivatives, but two classes of pyridine-derived agonists are known ([@B75]). The non-nucleoside A~1~AR agonist Capadenoson **17** (BAY68-4986), having an atypical 3,5-dicyanopyridine structure, was evaluated in patients with stable angina using an oral dose of 4 mg, once daily ([@B95]; [@B142]). However, Capadenoson was withdrawn from clinical trials for angina and for AF.

#### Heart failure

Rather than full agonists, an A~1~AR partial agonist Neladenoson **18** (in the form of a dipeptide ester prodrug **19**) is now being tested in patients with chronic heart failure ([@B73]; [@B41]; [@B112]; [@B157]). Compared with Capadenoson ([@B10]), Neladenoson is a more selective partial agonist for A~1~AR. Neladenoson has been shown to improve cardiac function without producing bradycardia, atrioventricular blocks, or undesirable effect on blood pressure ([@B112]; [@B157]). The rationale for using partial A~1~AR agonists is based on the observation that the activation of myocardial A~1~ARs by partial agonists protects cardiac function related to ischemia and reperfusion injury without producing severe side effects ([@B2]; [@B157]). A multiple dose study of Neladenoson (BAY 1067197) (ParSiFAL, 5 -- 40 mg oral dose, once daily) in heart failure is ongoing.

### MMPD **20**

#### Imaging

Numerous A~1~AR ligands have been in development for potential use in diagnosis of various conditions, such as depression, Parkinson's disease, Alzheimer's disease, epilepsy, ischemia, and sleep disorders. The A~1~AR is highly expressed in many brain regions, such as the hippocampus, neocortex, thalamus and basal ganglia ([@B60]). *In vivo* imaging of A~1~AR in the human brain is therefore an attractive approach for diagnosis, and various AR agonists and antagonists have been developed for PET brain imaging ([@B151]). Although varied AR subtype selectivities and agonist efficacies are seen with the class of atypical 3,5-dicyanopyridine ligands, partial agonist MMPD **20** was recently shown to be highly A~1~AR selective, with 16% maximal human A~1~AR activation, and suitable for the PET imaging in the rat brain ([@B75]). It has a relatively low molecular weight (373) and polar surface area (108 Å^2^), which allows it to cross the BBB. Typical ribose-containing A~1~AR agonists have limited utility to be administered therapeutically for CNS treatment due to their low degree of brain uptake from the periphery ([@B130]).

A~2A~AR-Selective Agonists
--------------------------

### Regadenoson **21**

#### Imaging

Regadenoson **21** (CVT-3146, Lexiscan) is a moderately selective, short acting A~2A~AR agonist that is administered i.v. for MPI ([@B122]). It was first approved as a pharmacologic stress agent in 2008. At present, it is the only synthetic AR agonist that is approved for human use, although it is not highly potent or selective for the A~2A~AR. Nevertheless, Regadenoson's A~2A~AR selectivity is higher in human than in mouse, in which it is actually 10-fold A~1~AR selective compared to A~2A~AR ([@B20]). The availability of an FDA-approved new chemical entity (NCE) allows it to be tested in diverse clinical trials for cardiovascular treatment and diagnosis (\>60 currently listed in [ClinicalTrials.gov](http://ClinicalTrials.gov), accessed 12-31-2018).

#### Sickle cell disease

In addition to their diagnostic application in MPI, A~2A~AR agonists have been considered for treatment of inflammation ([@B23]) and sickle cell disease (SCD, [@B55]). A~2A~AR activation in natural killer T (iNKT) cells is anti-inflammatory as demonstrated in a transgenic mouse model of SCD. However, A~2B~AR activation in erythrocytes is predicted to have a harmful effect in SCD. The effects of Regadenoson **21** as an A~2A~AR agonist in SCD patients were evaluated in a clinical trial, but there was no statistically significant benefit ([@B54]).

#### Lung transplantation

Murine lung ischemia reperfusion injury occurring via NADPH oxidase 2 (NOX2) and IL-17 is also attenuated by A~2A~AR agonist **26** ([@B135]), which has led to an ongoing clinical trial of Regadenoson **21** in lung transplantation. The safety of using Regadenoson for MPI in patients with mild to moderate COPD and asthma was established ([@B72]).

#### Glioblastoma

A~2A~AR agonists transiently increase BBB permeability ([@B96]), and this is being evaluated as a novel pharmacological approach to drug delivery to the brain. Regadenoson was tested clinically in an attempt to raise the concentration of the anticancer drug temozolomide in the brain interstitium, determined using microdialysis in glioblastoma patients ([@B83]).

### Spongosine (BVT.115959, CBT-1008) **22** and Other Naturally Occurring AR Agonists

#### Pain

Numerous other A~2A~AR agonists were studied in preclinical testing or clinical trials prior to the approval of Regadenoson. Among the first such agonists was the simple 2-methoxy derivative of adenosine, spongosine (BVT.115959) **22**, a marine natural product ([@B68]). Actually, spongosine is slightly selective for and equipotent at the human A~1~AR and A~3~AR. It was shown to be effective in a clinical trial for diabetic neuropathic pain (7 mg oral dose, 3X daily), which was terminated because the company discontinued small molecule research ([@B97]).

#### Inflammation

Activation of the A~2A~AR by endogenous adenosine provides benefit in animal models of inflammation and rheumatic disease, for example in rat models of osteoarthritis ([@B37]; [@B77]). Other naturally occurring adenosine or deoxyadenosine derivatives have been applied as AR agonists. Polydeoxyribonucleotide (PDRN, structure not shown), of molecular weight 80--200 KD and extracted from trout or salmon sperm, is degraded by plasma DNA nucleases or cell membrane-bound nucleases giving rise to nucleosides and nucleotides. It is asserted that the degraded products pharmacologically activate the A~2A~AR, based on antagonism by the relatively weak and non-selective A~2A~AR antagonist 3,7-dimethyl-1-propargylxanthine (DMPX). PRDN's therapeutic effects include tissue repairing, anti-ischemic, and anti-inflammatory, making it suitable in regenerative medicine and for treating diabetic foot ulcers. Topically applied PDRN was in a clinical trial for reducing inflammation to promote wound healing in cases of diabetic foot ulcers ([@B136]). Also, topically applied PDRN significantly reduced pain and increased joint function in an animal model of osteoarthritis and increased neurogenesis in a spinal cord injury model ([@B80]).

### Sonedenoson (MRE-0094) **23** and Binodenoson (WRC-0470, MRE-0470) **24**

#### Imaging

Many adenosine derivatives that proved to be A~2A~AR-selective agonists have bulky, hydrophobic substitution at the C2 position of adenine ([@B85]). A~2A~AR agonist Binodenoson **24** (≤ 1.5 μg/kg, i.v.) administered for MPI of patients with coronary artery disease did not cause the side effect of bronchoconstriction ([@B116]).

#### Wound healing

Sonedenoson (MRE-0094) **23** was effective in the treatment of poorly healing wounds in animal models ([@B153]), an A~2A~AR-agonist effect later found to be dependent on tissue plasminogen activator ([@B114]). A Phase 2 clinical trial of Sonedenoson administered as a topical gel for diabetic foot ulcers had poor enrollment and was terminated in 2008.

### Apadenoson (ATL-146e, BMS 068645) **25** and Evodenoson (ATL-313, DE-112) **26**

#### Imaging

Apadenoson **25** ([@B128]; [@B167]) was in several clinical trials for MPI and SCD, which has a component of hypoxia. Apadenoson contains a labile ester moiety, which is cleaved *in vivo* to limit its duration of action. Its more stable, urethane-containing congener Evodenoson (ATL-313) **26**, was developed as a candidate drug for treating multiple myeloma ([@B127]; [@B151]).

### UK-371104 **27** and UK-432097 **28**

#### Pulmonary inflammation

Intratracheal administration of A~2A~AR agonist UK-371104 **27**, with sterically bulky *N*^6^ and C2 substituents, in anesthetized guinea pig, inhibited the capsaicin-induced bronchoconstriction without affecting blood pressure ([@B149]). Thus, additional lung-focused A~2A~AR agonists were explored for treating lung inflammation.

UK-432097 **28** is a selective A~2A~AR agonist that was in a failed clinical trial for COPD ([@B110]), although its pharmacology is comparable to its preceding congener, UK-371104 **27**. UK-432097 as an inhaled dry powder was not efficacious in human trials (discontinued in 2008), possibly due to its agonist activity at the A~1~ and A~3~ARs, and/or its high MW (778), and multiple H-bond donor (7) and acceptor (13) groups reduced its bioavailability, even when administered directly in the lungs by inhalation. However, it displays a favorably slow off-rate from the receptor, which has been suggested to contribute to its sustained agonist effects ([@B78]). The extended *N*^6^ and C2 substituents of UK-432097 and its congeners interact with A~2A~AR extracellular regions to impede their dissociation. The bulky *N*^6^ and C2 substitutions of UK-432097 enabled the structural determination of its A~2A~AR complex ([@B164]).

### GW328267X **29**

#### Asthma and allergy

A dual A~2A~AR agonist and A~3~AR antagonist GW328267X **29** failed to show efficacy in a clinical trial for asthma (inhaled) and allergic rhinitis (intranasal) ([@B149]), despite its anti-inflammatory efficacy in animal models. Its structure is unusual in that it contains an ethyl-tetrazole group at the ribose 4′ position, thus contributing to its dual action at the two AR subtypes ([@B149]). Its side effects (hypotension, tachycardia) even when administered by inhalation were dose-limiting in the clinical trials. However, intravenous infusion of GW328267X in humans (52 μg/kg, over 5.5 h) resulted in a mechanism-related tachycardia that was ascribed to A~2A~AR activation in the carotid bodies, which was not alleviated upon prolonged agonist exposure. The lack of tachyphylaxis leading to prolonged tachycardia was not acceptable ([@B4]), and its clinical testing was discontinued. The translational failure of A~2A~AR agonists is likely due to their limited selectivity, especially their agonist activity at the A~1~AR. It has been suggested that A~1~AR antagonists and A~2A~AR agonists may have beneficial effects for asthma ([@B66]).

A~2B~AR-Selective Agonist
-------------------------

### BAY 60-6583 **30**

#### Ischemia, inflammation, diabetes, asthma, and cancer

Although there are no A~2B~AR agonists currently in clinical evaluation, animal models suggest its activation might result in beneficial effects in acute lung injury, ischemia and vascular leakage ([@B49]; [@B48]). The non-nucleoside (3,5-dicyanopyridine) agonist BAY 60-6583 **30** has been used as an *in vitro* and *in vivo* pharmacological probe, although its degree of efficacy and its species dependence of affinity/selectivity can vary ([@B63]). In some models, including insulin release in MIN6 mouse insulinoma cells, the compound was reported to act as an A~2B~AR antagonist. Therefore, highly selective and reliably efficacious A~2B~AR agonists are still lacking. Moreover, the signaling pathways activated or inhibited by the nominally G~s~-coupled A~2B~AR are complex and involve multiple G proteins ([@B65]).

Mast cell A~2B~AR activation might be useful in the treatment of asthma ([@B66]). In the intestines, kidney and other organs, this receptor has an anti-ischemic effect ([@B74]; [@B76]). A~2B~AR activation is predicted to have beneficial cardiovascular effects and maintain the endothelial cell barrier ([@B49]). BAY 60-6583 was shown to have protective effects in a model of myocardial reperfusion injury ([@B143]). A~2B~AR activation leading to the PI3K/Akt pathway is anti-inflammatory by shifting macrophages to an M2 phenotype. Pre-ischemic administration of BAY 60-6583 stimulated leukocyte PI3K/Akt in the mouse spleen to reduce myocardial reperfusion injury in an IL-10-dependent manner ([@B119]).

A~2B~AR activation might also be useful in treating T2D and atherosclerosis, and preventing vascular lesions due to smooth muscle cell proliferation after angioplasty ([@B100]; [@B139]). A~2B~AR KO mice displayed increased fatty liver pathology, tissue inflammation and insulin resistance due to the lack of this receptor in macrophages ([@B93]). A~2B~AR activation reduced inflammation and macrophage activation resulting from FFA ([@B38]). The receptor was highly upregulated in mice subjected to a high-fat diet (HFD), and A~2B~AR KO mice on this diet developed obesity and insulin resistance. BAY 60-6583 administered for 4 weeks HFD restored endocrine function and reduced inflammation. However, A~2B~AR gene expression was found to be elevated in cases of human gestational diabetes, but this observation did not establish whether an A~2B~AR agonist or antagonist would be more beneficial ([@B162]).

Although blocking the A~2B~AR is considered a target in conjunction with cancer immunotherapy, its activation also has been reported to reduce proliferation of cancer cells ([@B101]). A~2B~AR activation led to ERK1/2 dephosphorylation and reduced cell proliferation through inhibition of the MAPK signaling pathway in the MDA-MB-231 breast cancer cell line.

A~3~AR-Selective Agonists
-------------------------

### IB-MECA **31**

#### Autoimmune inflammatory diseases

A~3~AR agonists display anti-inflammatory and anticancer effects in various *in vivo* disease models ([@B37]; [@B89]). A~3~AR agonists stimulate chemotaxis in neutrophils through the leading edge, which could be pro-inflammatory. However, systemic A~3~AR agonist administration could actually have an anti-inflammatory effect by inhibiting neutrophil chemotaxis because of the non-directional agonist exposure ([@B25]).

IB-MECA (CF101, Piclodenoson) **31**, the first moderately selective A~3~ agonist ([@B62]), is being developed for the treatment of autoimmune anti-inflammatory diseases, including rheumatoid arthritis (RA) and psoriasis (both in Phase 3) ([@B56]). In Phase 2 trials, its action in RA and psoriasis compared favorably to existing treatments for those conditions, but it did not display serious adverse effects, as do the current treatments. In a comparison of 1, 2, and 4 mg oral IB-MECA doses in a 12-week Phase 2 psoriasis trial, the greatest patient improvement was observed with the 2 mg dose ([@B56]). Similarly in a Phase 2 RA trial, the middle (1 mg, compared to 0.1 and 4 mg) oral dose achieved the highest responses. Peripheral blood mononuclear cells (PBMCs) from psoriasis patients showed elevated A~3~AR expression. IB-MECA inhibited proliferation and formation of IL-17 and IL-23 in a human keratinocyte cell line ([@B31]). IB-MECA was previously in Phase 2 clinical trials for dry eye disease and glaucoma, 1 mg and 2 mg, respectively (oral, twice daily), which failed to demonstrate efficacy ([@B9]; [@B84]).

### Cl-IB-MECA **32**

#### Liver diseases

Cl-IB-MECA **32**, was initially shown to display a higher A~3~AR agonist selectivity than IB-MECA at the rat ARs. However, at the mA~3~AR, IB-MECA is more potent and selective than Cl-IB-MECA ([@B21]). Cl-IB-MECA (CF102, Namodenoson) is being developed for the treatment of liver conditions, including hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH) ([@B57]). A~3~AR agonists have apoptotic and anticancer effects *in vivo* induced by Wnt signaling deregulation ([@B12]). The US Food and Drug Administration and the European Medicines Agency granted fast track designation to **32** for the treatment of liver cancer. Cl-IB-MECA (up to a 25 mg oral dose) increased the median overall survival in patients with advanced HCC by 7.8 months in patients ([@B138]), which was improved over the current treatment. There were no serious adverse effects or dose-limiting toxicity. Secondarily, the trial examined using the A~3~AR as a predictive marker of the CF102 clinical response. The use of A~3~AR to prevent cytokine release syndrome in cancer immunotherapy has been proposed ([@B32]).

An anti-steatotic effect of Cl-IB-MECA in an HFD mouse model of NASH, induced by STZ administered 2 days after birth, was mediated via a molecular mechanism leading to decreased α-smooth muscle actin (αSMA, a marker of pathological fibroblasts) and cytokeratin 18 (CK-18, a predictor of NASH severity). A Phase 2 trial of CF-102 (12.5 and 25 mg oral doses, twice daily) for NASH treatment is underway.

#### Skeletal muscle protection

A~3~AR agonists, including Cl-IB-MECA, protect skeletal muscle in ischemic models in a phospholipase C-b2/b3-dependent manner ([@B166]).

### CP-608,039 **34** and CP-608,039 **35**

#### Cardioprotection

[@B40] reported that CP-608,039 **35** is a highly A~3~AR selective and water-soluble agonist that was being evaluated for the prevention of perioperative myocardial ischemic injury. This follows numerous other reports showing that A~3~AR activation protects ischemic cardiomyocytes by preconditioning ([@B104]).

Recently, selective A~3~AR deletion in mouse cardiomyocytes was used to demonstrate that activation by selective agonist CP-532,903 (**34**) of a myocardial A~3~AR provides ischemic tolerance that is dependent on K~ATP~ channels ([@B160]). This study resolves a long-standing controversy by showing that a protective A~3~AR is present in adult ventricular cardiomyocytes, although expressed at very low levels (copy number of 85 per 100 ng total RNA versus 12,830 for the A~1~AR).

### MRS5698 **36**

#### Pain

As noted above, A~1~AR agonists and PAMs are already under consideration for pain treatment. The efficacy of A~3~AR agonists for chronic pain was first explored depth in 2011 ([@B26]). The approach of using A~3~AR agonists for pain treatment was initially controversial, as A~3~AR activation had been described in earlier review papers as an uninteresting target or even an anti-target for pain relief ([@B118]; [@B90]). Reasons for this premature characterization were: truly selective A~3~AR agonists were not initially available and the A~3~AR causes release of inflammatory mediators, e.g., histamine and serotonin, from peripheral mast cells in rodents, but not human and other species ([@B8]; [@B107]; [@B66]). These mediators can contribute to inflammation in mouse and rat, and [@B129] concluded that A~3~AR activation induces pain and paw oedema. However, consistent with the now well-documented action of A~3~AR activation in various chronic pain models, A~3~AR KO mice had a lower pain threshold in the hind-paw hot-plate test (40% greater latency, [@B53]). Curiously, there was no difference between A~3~AR KO and WT mice in the acute pain response in the tail-flick test.

The two selective A~3~AR agonists in already clinical trials, IB-MECA and Cl-IB-MECA, at high doses *in vivo* might interact with other ARs, as has been observed in experimental models ([@B59]). A new series of C2-extended (N)-methanocarba analogs displayed even greater A~3~AR selectivity, estimated to be in the range of at least 10,000-fold in comparison to other ARs ([@B89]). Among these agonists is MRS5698 **33**, which has been shown to reduce chronic neuropathic pain, including oxaliplatin-induced neuropathic pain ([@B108]; [@B159]). MRS5698 has many drug-like properties -- it is non-toxic and relatively stable *in vivo*, except that its oral bioavailability in the rat is only 5%F ([@B145]). Nevertheless, by various modes of administration it is efficacious in pain models *in vivo*, including chronic constriction injury-induced, chemotherapy-induced and cancer-induced. Its ability to reduce chronic hyperalgesia is not affected by the A~3~AR-induced histamine release observed in rodent but not human mast cells ([@B22]).

### MRS5980 **37**

#### Pain

MRS5980 **37** is a highly selective C2-arylethynyl (N)-methanocarba A~3~AR agonist, which has been demonstrated to be highly efficacious in *in vivo* pain models following administered by oral gavage, with a protective effect lasting up to 3 h ([@B144]; [@B90]), and its metabolomics has been studied ([@B52]). The 2-chlorothienyl group is stable *in vivo*, and the aryl alkyne group was shown to be not highly reactive. MRS5980 and other A~3~AR agonist were shown to indirectly block a pro-nociceptive N-type Ca^2+^ calcium channels, a proven target in controlling pain, and cell excitability in the spinal cord dorsal horn ([@B34]). Thus, therapeutic application of A~3~AR agonists appears to be a promising approach for treating pain of different etiologies.

### LJ-529 **33** and MRS4322 **38**

#### Stroke

[@B156] found that both A~1~AR and A~3~AR agonists have cerebroprotective properties in a model of gerbil forebrain ischemia. An (N)-methanocarba nucleoside MRS4322 **38** was proposed in a patent application ([@B99]) as a treatment for stroke and traumatic brain injury. The nucleoside appears to act through the A~3~AR, to which it binds in the μM range, because a selective A~3~AR antagonist propyl 6-ethyl-5-((ethylthio)carbonyl)-2-phenyl-4-propylnicotinate (MRS1523) diminished the benefit of reduced stroke lesions. LJ-529 **33** (4′-thio-Cl-IB-MECA) is a selective A~3~ adenosine agonist that was shown to be protective in a rat stroke model and inhibited brain migration of inflammatory cells ([@B28]). However, platelet A~2A~AR activation by LJ-529 increased the bleeding risk.

AR Allosteric Enhancers (PAMs)
------------------------------

PAMs of the A~1~AR and A~3~AR have been the subject of preclinical and clinical evaluation ([Figure 3](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). PAMs, in principle, may remain silent until a large rise in the extracellular adenosine occurs, at which time the PAM would amplify adenosine's action at a particular AR subtype. Thus, PAMs are described as temporally and spatially specific modulators ([@B67]). Also, PAMs tend to be more subtype selective than orthosteric agonists, because their non-canonical binding regions on the GPCRs are those that have the most diverse sequences within the receptor family ([@B152]).

![A~3~AR- (**31**-**38**) selective agonists and allosteric enhancers (PAMs) of the A~1~AR (**39**, **40**) and A~3~AR (**41**).](fncel-13-00124-g003){#F3}

### T-62 **39**

Benzoylthiophenes are the earliest and most extensively studied class of A~1~AR PAMs, and they have allosteric agonist properties as well as enhancing the effect of other A~1~AR agonists ([@B155]; [@B86]). The benzoylthiophenes Just as A~1~AR agonists have been considered for pain treatment, a representative benzoylthiophene T-62 **39** entered a clinical trial for postherpetic neuropathic pain in 2008 that was discontinued because of its lack of efficacy ([@B70]). Also, some patients displayed transient, elevated liver transaminases. Nevertheless, T-62 reduced hypersensitivity in animal models of neuropathic pain. The structural basis for recognition of benzoylthiophene PAMs involving A~1~AR extracellular loops (ELs) has been predicted using Gaussian accelerated molecular dynamics ([@B113]).

### TRR469 **40**

#### Pain

A later generation benzoylthiophene TRR469 **40** was shown to be an A~1~AR PAM that increases the affinity of A~1~AR agonists ([@B155], [@B154]). It reduced pain, comparably to morphine, in writhing and formalin tests and in chronic STZ-induced diabetic neuropathy, and it displayed fewer behavioral side effects than an A~1~AR orthosteric agonist. Furthermore, the same A~1~AR PAM was anxiolytic in four behavioral models in the mouse, in a manner comparable to the anxiolytic drug diazepam ([@B154]). This activity of **40**, which was blocked by a selective A~1~AR antagonist (DPCPX), is consistent with the previously noted anxiolytic activity of A~1~AR agonists.

### LUF6000 **41**

#### Inflammation and erectile dysfunction

LUF6000 **41** is a imidazoquinolinamine A~3~AR allosteric enhancer (PAM). It enhanced the maximal efficacy of A~3~AR agonists but had no agonism on its own ([@B67]). Its interaction with the A~3~AR was species-dependent ([@B43]). Although it was more efficacious in human, canine and rabbit than in rodent species, it was shown to produce an anti-inflammatory effect in rat models of adjuvant-induced arthritis and iodoacetate-induced osteoarthritis and in a mouse model of concanavalin A-induced liver inflammation ([@B30]). The molecule is termed CF602 and is on a translational path for treatment of erectile dysfunction ([@B33]).

Conclusion
==========

The structural and pharmacological features of key AR agonists and positive allosteric modulators (PAMs) have been summarized, with an emphasis on molecules that have been in humans or that were considered for human testing. From the thousands of selective AR agonists or allosteric enhancers reported, there are few translational successes. Many AR agonists have been in clinical trials for disease treatment or diagnosis, but only two are approved for human use, i.e., short-acting agonists adenosine and Regadenoson. However, new concepts and compounds are currently being developed and applied toward preclinical and clinical evaluation, and initial results are encouraging. AR agonists for treating inflammation, pain, cancer, NASH, angina, sickle cell disease, ischemic conditions and diabetes are under development. Multiple clinical trials with two A~3~AR agonists are ongoing.
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